Peter Attia MDPros and cons of GLP-1 weight loss drugs and metformin as a geroprotective agent [AMA 45 sneak peek]
Episode Details
EPISODE INFO
- Released
- March 13, 2023
- Duration
- 27m
- Channel
- Peter Attia MD
- Watch on YouTube
- ▶ Open ↗
EPISODE DESCRIPTION
Watch the full episode and view show notes here: http://bit.ly/3Tap47T Become a member to receive exclusive content: https://peterattiamd.com/subscribe/ Sign up to receive Peter's email newsletter: https://peterattiamd.com/newsletter/ In this “Ask Me Anything” (AMA) episode, Peter focuses the discussion on two topics getting a lot of attention recently. He first dives deep into GLP-1 agonists, most notably semaglutide and tirzepatide, which originally came to market as diabetes drugs but are now being studied and prescribed for weight loss. He walks through the data and compares the effectiveness of the two drugs, the side effects, and perhaps more importantly, his reservations around wide use of these drugs and who he would consider to be a candidate for them. Next, Peter discusses how metformin, another drug originally brought to market for diabetes management, gained popularity as a potential longevity drug even for non-diabetics. Peter gives his take on this possibility and reviews data from a more recent study investigating the question of whether metformin should be used for general “geroprotection.” In this sneak peek, we discuss: 00:00 - Intro 00:08 - The hype around semaglutide, tirzepatide, and other GLP-1 agonists for weight loss 04:09 - Overview of GLP-1 agonists and why these drugs are getting so much attention 12:20 - Defining the term “geroprotective” 14:08 - Semaglutide: background, brand names, indications, and more 19:10 - Tirzepatide: background, brand names, indications, and more In the full episode, we also discuss: -How semaglutide and tirzepatide compare in their efficacy in terms of weight loss and other metabolic health metrics; -Data showing sustained weight loss and improved metabolic metrics with after more than a year of using semaglutide and tirzepatide; -What happens to body weight when a patient discontinues the medication?; -Noteworthy side effects of GLP-1 agonists and similar classes of drugs; -Increased resting heart rate and other concerning trends in patients using GLP-1 agonists; -Changes in body composition (body fat and lean muscle) in patients on GLP-1 agonists; -Possible reasons for the loss of lean muscle mass and tips for protecting lean mass; -GLP-1 agonists and thyroid cancer; -Who might be a candidate for GLP-1 agonists?; -The large financial cost of this class of drugs; -Metformin as a geroprotective drug: origin of the idea that metformin could be a longevity agent even for non-diabetic patients; -A 2022 study on metformin sheds more light on the question of whether metformin should be used for “geroprotection” in non-diabetics; -Peter’s current approach with metformin for his patients; and -More. -------- About: The Peter Attia Drive is a weekly, ultra-deep-dive podcast focusing on maximizing health, longevity, critical thinking…and a few other things. With over 45 million episodes downloaded, it features topics including fasting, ketosis, Alzheimer’s disease, cancer, mental health, and much more. Peter is a physician focusing on the applied science of longevity. His practice deals extensively with nutritional interventions, exercise physiology, sleep physiology, emotional and mental health, and pharmacology to increase lifespan (delay the onset of chronic disease), while simultaneously improving healthspan (quality of life). Learn more: https://peterattiamd.com Connect with Peter on: Facebook: http://bit.ly/PeterAttiaMDFB Twitter: http://bit.ly/PeterAttiaMDTW Instagram: http://bit.ly/PeterAttiaMDIG Subscribe to The Drive: Apple Podcast: http://bit.ly/TheDriveApplePodcasts Overcast: http://bit.ly/TheDriveOvercast Spotify: http://bit.ly/TheDriveSpotify Google Podcasts: http://bit.ly/TheDriveGoogle Disclaimer: This podcast is for general informational purposes only and does not constitute the practice of medicine, nursing, or other professional healthcare services, including the giving of medical advice. No doctor-patient relationship is formed. The use of this information and the materials linked to this podcast is at the user's own risk. The content on this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard or delay in obtaining medical advice for any medical condition they have, and they should seek the assistance of their healthcare professionals for any such conditions. I take conflicts of interest very seriously. For all of my disclosures and the companies I invest in or advise, please visit my website where I keep an up-to-date and active list of such companies.
SPEAKERS
Peter Attia
hostPhysician and host of The Drive podcast, focusing on longevity, metabolic health, and preventive medicine.
EPISODE SUMMARY
In this episode of Peter Attia MD, featuring Peter Attia, Pros and cons of GLP-1 weight loss drugs and metformin as a geroprotective agent [AMA 45 sneak peek] explores peter Attia Explains GLP-1 Drugs, Semaglutide, Tirzepatide, and Metformin's Geroprotective Role Peter Attia says semaglutide and its relatives are now the most talked-about drugs, a topic his team studied as early as spring 2020 and he now holds a much stronger view on.
RELATED EPISODES
